Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients

Resaz, Roberta; Cangelosi, Davide; Segalerba, Daniela; Morini, Martina; Uva, Paolo; Bosco, Maria Carla; Banderali, Giuseppe; Estrella, Ana; Wanner, Corbinian; Weinstein, David A.; Sechi, Annalisa; Paci, Sabrina; Melis, Daniela; Rocco, Maja Di; Lee, Young Mok; Eva, Alessandra

doi:10.3390/ijms23010328

Cited by 5 publications

(4 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A great research effort in recent years has focused on the analysis of EV cargo to identify new predictors of disease development/evolution and response to therapy in several clinical settings [55,62,97,[116][117][118][119][120][121], including in patients affected by adult arthritides [56,86,122]. However, EV-miR expression and potential as biomarkers in JIA have begun to be analyzed only in the last year.…”

Section: Jia-derived Ev-mirsmentioning

confidence: 99%

MicroRNAs in Juvenile Idiopathic Arthritis: State of the Art and Future Perspectives

Pelassa

Raggi

Rossi

et al. 2023

Biology

Self Cite

View full text Add to dashboard Cite

Juvenile Idiopathic Arthritis (JIA) represents the most common chronic pediatric arthritis in Western countries and a leading cause of disability in children. Despite recent clinical achievements, patient management is still hindered by a lack of diagnostic/prognostic biomarkers and targeted treatment protocols. MicroRNAs (miRNAs) are short non-coding RNAs playing a key role in gene regulation, and their involvement in many pathologies has been widely reported in the literature. In recent decades, miRNA’s contribution to the regulation of the immune system and the pathogenesis of autoimmune diseases has been demonstrated. Furthermore, miRNAs isolated from patients’ biological samples are currently under investigation for their potential as novel biomarkers. This review aims to provide an overview of the state of the art on miRNA investigation in JIA. The literature addressing the expression of miRNAs in different types of biological samples isolated from JIA patients was reviewed, focusing in particular on their potential application as diagnostic/prognostic biomarkers. The role of miRNAs in the regulation of immune responses in affected joints will also be discussed along with their potential utility as markers of patients’ responses to therapeutic approaches. This information will be of value to investigators in the field of pediatric rheumatology, encouraging further research to increase our knowledge of miRNAs’ potential for future clinical applications in JIA.

show abstract

Section: Jia-derived Ev-mirsmentioning

confidence: 99%

MicroRNAs in Juvenile Idiopathic Arthritis: State of the Art and Future Perspectives

Pelassa

Raggi

Rossi

et al. 2023

Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In neonatology, miRNAs from cord blood showed a very low correlation with maternal blood miRNAs expression but instead they appeared to be powerful early biomarkers of child health ( Cretoiu et al, 2016 ; Dypas et al, 2020 ). Circulating miRNAs are also considered good diagnostic tools for example in celiac disease and its treatment ( Felli et al, 2022 ) or to detect the evolution of liver diseases ( Calkins et al, 2020 ; Resaz et al, 2021 ; Nagura et al, 2022 ).…”

Section: Serum/plasma Mirnasmentioning

confidence: 99%

Improving the Diagnostic Potential of Extracellular miRNAs Coupled to Multiomics Data by Exploiting the Power of Artificial Intelligence

et al. 2022

View full text Add to dashboard Cite

In recent years, the clinical use of extracellular miRNAs as potential biomarkers of disease has increasingly emerged as a new and powerful tool. Serum, urine, saliva and stool contain miRNAs that can exert regulatory effects not only in surrounding epithelial cells but can also modulate bacterial gene expression, thus acting as a “master regulator” of many biological processes. We think that in order to have a holistic picture of the health status of an individual, we have to consider comprehensively many “omics” data, such as miRNAs profiling form different parts of the body and their interactions with cells and bacteria. Moreover, Artificial Intelligence (AI) and Machine Learning (ML) algorithms coupled to other multiomics data (i.e., big data) could help researchers to classify better the patient’s molecular characteristics and drive clinicians to identify personalized therapeutic strategies. Here, we highlight how the integration of “multiomic” data (i.e., miRNAs profiling and microbiota signature) with other omics (i.e., metabolomics, exposomics) analyzed by AI algorithms could improve the diagnostic and prognostic potential of specific biomarkers of disease.

show abstract

“…The release of exosomes is regulated by specific stimuli, and their cargo reflects the producing cell [7]. Indeed, exosomes are defined as the bioprint of the cell of origin and, thus, the study of their content allows to gain accurate information of primary tumor features [8][9][10]. Indeed, exosomes represent a source for both diagnostic and prognostic markers in several human diseases [8][9][10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, exosomes are defined as the bioprint of the cell of origin and, thus, the study of their content allows to gain accurate information of primary tumor features [8][9][10]. Indeed, exosomes represent a source for both diagnostic and prognostic markers in several human diseases [8][9][10][11][12][13][14][15]. To gain insight into the characteristics of NB for improving diagnosis and treatment, we performed proteomic analysis of the exosomes released in the blood of NB patients.…”

Section: Introductionmentioning

confidence: 99%

Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients

Morini,

Raggi,

Bartolucci

et al. 2023

Cells

Self Cite

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most common extracranial solid tumor during infancy, causing up to 10% of mortality in children; thus, identifying novel early and accurate diagnostic and prognostic biomarkers is mandatory. NB-derived exosomes carry proteins (Exo-prots) reflecting the status of the tumor cell of origin. The purpose of this study was to characterize, for the first time, the Exo-prots specifically expressed in NB patients associated with tumor phenotype and disease stage. We isolated exosomes from plasma specimens of 24 HR-NB patients and 24 low-risk (LR-NB) patients at diagnosis and of 24 age-matched healthy controls (CTRL). Exo-prot expression was measured by liquid chromatography–mass spectrometry. The data are available via ProteomeXchange (PXD042422). The NB patients had a different Exo-prot expression profile compared to the CTRL. The deregulated Exo-prots in the NB specimens acted mainly in the tumor-associated pathways. The HR-NB patients showed a different Exo-prot expression profile compared to the LR-NB patients, with the modulation of proteins involved in cell migration, proliferation and metastasis. NCAM, NCL, LUM and VASP demonstrated a diagnostic value in discriminating the NB patients from the CTRL; meanwhile, MYH9, FN1, CALR, AKAP12 and LTBP1 were able to differentiate between the HR-NB and LR-NB patients with high accuracy. Therefore, Exo-prots contribute to NB tumor development and to the aggressive metastatic NB phenotype.

show abstract

Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients

Cited by 5 publications

References 62 publications

MicroRNAs in Juvenile Idiopathic Arthritis: State of the Art and Future Perspectives

MicroRNAs in Juvenile Idiopathic Arthritis: State of the Art and Future Perspectives

Improving the Diagnostic Potential of Extracellular miRNAs Coupled to Multiomics Data by Exploiting the Power of Artificial Intelligence

Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients

Contact Info

Product

Resources

About